Abstract
Thrombophilia is the term now used to describe predisposition to increased risk of venous and occasionally arterial thromboembolism due to hematological abnormalities. It can be a multifactorial disorder where congenital defects of anticoagulant or procoagulant factors may be combined with acquired hematological abnormalities. It should be considered in patients with a documented unexplained thrombotic episode or a positive family history. The aim of this document is to provide guidelines for investigation and management of patients with thrombophilia in the presence or absence of venous thromboembolism (VTE).
Publication types
-
Consensus Development Conference
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Activated Protein C Resistance / physiopathology
-
Antiphospholipid Syndrome / epidemiology
-
Europe / epidemiology
-
Factor V / genetics
-
Factor VIII / analysis
-
Hormone Replacement Therapy / adverse effects
-
Humans
-
Hyperhomocysteinemia / epidemiology
-
Mutation
-
Protein S / analysis
-
Recurrence
-
Thrombophilia / complications*
-
Thrombophilia / diagnosis
-
Thrombophilia / epidemiology
-
Thrombophilia / physiopathology
-
Venous Thrombosis / etiology*
-
Venous Thrombosis / physiopathology
Substances
-
Protein S
-
factor V Leiden
-
Factor V
-
Factor VIII